- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01818310
Safety and Efficacy Study of Autologous Bone Marrow Aspirate Concentrate for No-Option Critical Limb Ischemia (DIALEG)
Randomised Clinical Study of Safety and Efficacy of Autologous Bone Marrow Aspirate Concentrate (BMAC) for No-option_critical Limb Ischemia in Type-II Diabetes Mellitus Patients. (DIALEG)
Study Overview
Status
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Ostrava, Czechia, 708 52
- University Hospital Ostrava
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- type 2 diabetes mellitus
- diagnosis of critical limb ischemia
- non-healing defect on the study limb
- ABI value < 50 mmHg or ABI< 0.4
- TBI value < 40 mmHg or TBI < 0.4
- TcPO2 < 20 mmHg in supine position
- no other suitable surgical or re-vascularization procedure
- age > 18 years
- signed Informed Consent
Exclusion Criteria:
- non-signing of the Informed Consent
- anticipated life expectancy < 6 months
- history of bone-marrow disease
- renal failure or dialysis dependency
- known malignant disease
- health risks excluding the possibility of general anaesthesia or sedation
- life-threatening ischaemic heart disease
- vast necrosis of the index limb
- active infectious disease, or ATB treatment
- treatment with immunosupressives
- pregnancy, breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A: Intramuscular
Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml. The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes. |
Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml. The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes. |
Experimental: Group B: Intraarterial
Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.
|
Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.
|
Experimental: Group C: Intravenous
Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.
|
Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.
|
Other: Group D: Control-standard treatment
Group D: Control Group Study subjects in Group D will receive a standard treatment for NO-option CLI.
|
Group D: Control Group Control Group - no experimental intervention, standard endovascular treatment or bypass surgery or maximum medicamentous treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Amputation-free survival
Time Frame: 18 months
|
The data for Primary outcome will be collected throughout the first 18 months of the study.
The assessed parameters will include amputation-free survival in order to verify the safety and efficacy of the treatment.
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tissue perfusion parameters
Time Frame: 4 years
|
The efficacy of BMAC application will be evaluated throughout the whole course of the clinical trial, with final assessment at the end of the trial.
|
4 years
|
Clinical outcome classification
Time Frame: 4 years
|
The efficacy of BMAC application will be evaluated throughout the whole course of the clinical trial, with final assessment at the end of the trial. - Improvement of the Rutherford scale of CLI |
4 years
|
Functional angiogenesis imaging outcome
Time Frame: 4 years
|
The efficacy of BMAC application will be evaluated throughout the whole course of the clinical trial, with final assessment at the end of the trial. - Increase of the number and quality of newly created vessels measured according to digital subtraction angiography (DSA) or MR-angiography (in allergic patients) |
4 years
|
Quality of life outcome
Time Frame: 4 years
|
The efficacy of BMAC application will be evaluated throughout the whole course of the clinical trial, with final assessment at the end of the trial.
|
4 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in lymphocyte subsets and levels of inflammatory and antiinflammatory cytokines in each of the groups.
Time Frame: 24 months
|
The immune response of study subjects will be monitored following the transplantation of stem cells, together with the periphery lymphocyte function (T-cells, B-cells, NK-cells). Immune response parameters, (i.e. parameters of lymphocytar blastic transformation) |
24 months
|
Metabolic response
Time Frame: 24 months
|
The following laboratory parameters throughout the clinical trial:
|
24 months
|
Blood glucose and pancreatic function response
Time Frame: 24 months
|
The following parameters will be monitored in the study subjects:
|
24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Vaclav Prochazka, MD, PhD, MSc, University Hospital Ostrava
Publications and helpful links
General Publications
- Dormandy J, Heeck L, Vig S. The natural history of claudication: risk to life and limb. Semin Vasc Surg. 1999 Jun;12(2):123-37.
- Clair DG, Dayal R, Faries PL, Bernheim J, Nowygrod R, Lantis JC 2nd, Beavers FP, Kent KC. Tibial angioplasty as an alternative strategy in patients with limb-threatening ischemia. Ann Vasc Surg. 2005 Jan;19(1):63-8. doi: 10.1007/s10016-004-0136-0.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012-T2DM-CLI
- 2012-001825-28 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Critical Lower Limb Ischemia
-
Mansoura UniversityCompletedCritical Lower Limb IschemiaEgypt
-
Egyptian Biomedical Research NetworkCompletedCritical Lower Limb Ischemia
-
Medtronic EndovascularCompletedCritical Lower Limb IschemiaGermany, Belgium, Netherlands, Switzerland, Austria, Italy
-
R3 Vascular Inc.RecruitingCritical Limb Ischemia | Critical Lower Limb Ischemia | Critical Limb-Threatening IschemiaAustralia
-
Assiut UniversityNot yet recruitingLower Limb Ischemia Critical
-
Kafrelsheikh UniversityActive, not recruitingCritical Lower Limb Ischemia | AngioplastyEgypt
-
Ryazan State Medical UniversityRecruiting
-
Vascular Investigation Network Spanish Society...Hospital Clínico Universitario de ValladolidCompletedPostoperative Complications | Critical Lower Limb IschemiaSpain
-
Micro Medical Solution, Inc.RecruitingPeripheral Arterial Disease | Peripheral Artery Disease | Critical Limb Ischemia | Critical Lower Limb IschemiaAustria, Belgium, Germany, Italy, Netherlands
-
University of ManitobaMitsubishi-Rayon-CleansuiUnknownFoot Ulcer | Critical Limb Ischemia | Critical Lower Limb Ischemia | Skin UlcerationCanada
Clinical Trials on Group A: Intramuscular
-
University of MichiganNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingAmputation | Amputation NeuromaUnited States
-
Instituto de Investigación Hospital Universitario...Hospital Universitario La PazCompletedNonrevascularizable Critical Ischemia of the Lower LimbsSpain
-
Riphah International UniversityCompletedAutism Spectrum DisorderPakistan
-
The University of Texas Health Science Center,...National Institute for Occupational Safety and Health (NIOSH/CDC)Completed
-
Kahramanmaras Sutcu Imam UniversityCompletedPain | Interleukin | Vessels; VaricoseTurkey
-
Manuel RodríguezUnknownBrain IschemiaSpain
-
Zhu WeimingRecruiting
-
Oxford University Hospitals NHS TrustUniversity Hospital Southampton NHS Foundation Trust; University Hospital BirminghamCompletedAtrial Fibrillation | Cardiac ArrhythmiaUnited Kingdom
-
Riphah International UniversityCompleted
-
Western University, CanadaCompleted